Psoriasis, metabolic syndrome and its components;Psoriasis, syndrome métabolique et ses composants

Annales de Dermatologie et de Venereologie

Volumn 135, Issue SUPPL. 4, 2008, Pages 235-242

  Ortonne, J P ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Cardiovascular risk; Diabetes; Metabolic syndrome; Obesity; Psoriasis

Indexed keywords

ARTICLE; CHRONIC INFLAMMATION; COMORBIDITY; DIABETES MELLITUS; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; METABOLIC SYNDROME X; MORTALITY; OBESITY; PATHOGENESIS; PATHOLOGY; PREVALENCE; PSORIASIS; TH1 CELL; VASCULAR DISEASE; DYSLIPIDEMIA; INFLAMMATION; PATHOPHYSIOLOGY; REVIEW;

COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; MYOCARDIAL INFARCTION; OBESITY; PSORIASIS;

EID: 48849107322     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(08)70541-6     Document Type: Article

References (35)

1. Sommer D.M., Jenisch S., Suchan M., Christophers E., and Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
2. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157 (2007) 68-73
3. Naldi L., Chatenoud L., Linder D., Belloni Fortina A., Peserico A., Virgili A.R., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
4. Sato R, Piercy J, Kay S, Walker S, Singh A. Higher psoriasis disease severity is associated with increased co-morbidities in Europe. FC17.7. EADV Rhodes October 4-8. 2006.
5. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172 (1986) 298-304
6. Herron M.D., Hinckley M., Hoffman M.S., Papenfuss J., Hansen C.B., Callis K.P., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141 (2005) 1527-1534
7. Setty A.R., Curhan G., and Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 167 (2007) 1670-1675
8. Mallbris L., Akre O., Granath F., Yin L., Lindelof B., Ekbom A., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19 (2004) 225-230
9. McGowan J.W., Pearce D.J., Chen J., Richmond D., Balkrishnan R., and Feldman S.R. The skinny on psoriasis and obesity. Arch Dermatol 141 (2005) 1601-1602
10. Sterry W., Strober B.E., and Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 157 (2007) 649-655
11. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., and Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
12. Mallbris L., Granath F., Hamsten A., and Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 54 (2006) 614-621
13. Mallbris L., Ritchlin C.T., and Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 8 (2006) 355-363
14. Robinson D.J., Bala M., Wu J., Paramore L.C., Fraeman K.H., and Kimball A.B. Cardiovascular risk among US psoriasis patients: evidence from two large healthcare databases. J Invest Dermatol 126 (2006) Abstract 302
15. Shapiro J., Cohen A.D., David M., Hodak E., Chodik G., Viner A., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56 (2007) 629-634
16. Jucci A., Vignini M., Pelfini C., Criffo A., and Fratino P. Psoriasis and insulin secretion. Preliminary results. Arch Dermatol Res 257 (1977) 239-246
17. Farber E.M., and Nall M.L. The natural history of psoriasis in 5 600 patients. Dermatologica 148 (1974) 1-18
18. Farber E.M., Bright R.D., and Nall M.L. Psoriasis. A questionnaire survey of 2.144 patients. Arch Dermatol 98 (1968) 248-259
19. Henseler T., and Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13 (1985) 450-456
20. Reynoso-von Drateln C., Martinez-Abundis E., Balcazar-Munoz B.R., Bustos-Saldana R., and Gonzalez-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 48 (2003) 882-885
21. Ucak S., Ekmekci T.R., Basat O., Koslu A., and Altuntas Y. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 20 (2006) 517-522
22. Preece J.F. Raised blood pressure and psoriasis. J R Coll Gen Pract 27 (1977) 713-715
23. Ena P., Madeddu P., Glorioso N., Cerimele D., and Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 40 (1985) 199-205
24. Sakai R., Matsui S., Fukushima M., Yasuda H., Miyauchi H., and Miyachi Y. Prognostic factor analysis for plaque psoriasis. Dermatology 211 (2005) 103-106
25. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., and Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
26. McDonald C.J., and Calabresi P. Thromboembolic disorders associ-ated with psoriasis. Arch Dermatol 107 (1973) 918
27. Markuszeski L., Bissinger A., Janusz I., Narbutt J., Jedrzejowska A.S., and Zalewska A. Heart rate and arrhythmia in patients with psoriasis vulgaris. Arch Med Res 38 (2007) 64-69
28. Reddy S.M., and Bingham Iii C.O. Outcome measures in psoriatic ar-thritis clinical trials. Curr Rheumatol Rep 7 (2005) 299-305
29. Han C., Robinson Jr. D.W., Hackett M.V., Paramore L.C., Fraeman K.H., and Bala M.V. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33 (2006) 2167-2172
30. Gonzalez-Juanatey C., Llorca J., Miranda-Filloy J.A., Amigo-Diaz E., Testa A., Garcia-Porrua C., et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57 (2007) 287-293
31. Gonzalez-Juanatey C., Llorca J., Amigo-Diaz E., Dierssen T., Martin J., and Gonzalez-Gay M.A. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57 (2007) 1074-1080
32. Kimhi O., Caspi D., Bornstein N.M., Maharshak N., Gur A., Arbel Y., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36 (2007) 203-209
33. Peters M.J., van der Horst-Bruinsma I.E., Dijkmans B.A., and Nurmohamed M.T. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34 (2004) 585-592
34. Sattar N., Crompton P., Cherry L., Kane D., Lowe G., and McInnes I.B. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 56 (2007) 831-839
35. Bernstein L.E., Berry J., Kim S., Canavan B., and Grinspoon S.K. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166 (2006) 902-908